Darleukin (L19IL2) is a fully-human immunostimulatory product consisting of the human anti-EDB antibody L19, fused to the human cytokine, interleukin-2 (IL2). Recombinant IL2 is an approved biopharmaceutical (“Proleukin®”; Clinigen) and the fusion of IL2 to the human vascular targeting L19 antibody has demonstrated a striking superiority compared to non-targeted IL2 in preclinical models of cancer. IL2 directly stimulates immune effector cells and stromal cells at the tumor site and enhances tumor cell killing by lymphocytes and NK cells.
Darleukin has already been tested in clinical studies in Melanoma and Pancreatic Cancer. More recently, the combination of Darleukin with other immunocytokines (e.g. the combination with L19TNF in NidlegyTM), with chemotherapeutic drugs, or with radiation therapy has shown potent synergistic activity in preclinical and clinical studies.
ONGOING CLINICAL TRIALS
Ongaro et al., (2020) Oncotarget, 11, 3698-3711
Weide et al. (2019) Cancer Immunol Immunother, 68, 1547-1559
Zegers et al. (2015) Clin Cancer Res, 21, 1151-60
Rekers et al. (2015) Radiother Oncol, 116, 438-42
Rekers et al. (2015) Oncoimmunology, 4, p. e1021541
Danielli et al. (2015) Cancer Immunol Immunother, 64, 999-1009
Weide et al. (2014) Cancer Immunol Res, 2, 668-78
Schwager et al. (2013) J Invest Dermatol, 133, 751-8
Eigentler et al. (2011) Clin Cancer Res, 17, 7732-42
Eigentler et al. (2011) J Clin Oncol, 29, 2531
Johannsen et al. (2010) Eur J Cancer, 46, 2926-35
Schliemann et al. (2009) Blood, 113, 2275-2283
Carnemolla et al. (2002) Blood, 99, 1659-65